Convergence Insufficiency Neuro-mechanism in Adult Population Study Randomized Clinical Trial: Clinical Outcome Results.
Tara L Alvarez, Mitchell Scheiman, Elio M Santos...
https://pubmed.ncbi.nlm.nih.gov/33186192/Actively Recruiting
Led by Midwestern University · Updated on 2024-12-02
150
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying adults aged 18 to 40 with symptomatic convergence insufficiency to evaluate the effectiveness of non-invasive brain stimulation compared to traditional office-based vergenceaccommodative therapy. The trial aims to find out if brain stimulation can shorten therapy time from 12 weeks to 8 weeks, and whether brain stimulation alone is as effective as the therapy in improving symptoms. Participants will be assigned randomly to one of three groups to compare treatment effects. The study involves three groups one receives 8 sessions of non-invasive brain stimulation combined with 8 weeks of office-based vergenceaccommodative therapy another receives 8 sessions of sham placebo stimulation with 8 weeks of the therapy and the third group receives 8 sessions of brain stimulation only. Brain stimulation is delivered using an anodal transcranial direct current device applying a 2 milliamp current over the left frontal eye field for about 20 minutes per session. Therapy includes weekly 60-minute in-office sessions and prescribed daily home exercises. Participants will be monitored through near point of convergence NPC and positive fusional vergence PFV measurements at 4, 6, and 8 weeks during treatment, and again at 6 and 12 months after treatment ends. Symptom surveys will also be collected at 8 weeks and during follow-up. The study includes informed consent, baseline vision assessments, and safety monitoring throughout the trial, which is sponsored by Midwestern University and runs until 2028.
CONDITIONS
Non-invasive Brain Stimulation for Treating Symptomatic Convergence Insufficiency
A
Arijit Chakraborty, PhD
A
Adrienne C Quan, OD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Midwestern University
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Non-invasive Brain Stimulation Plus Office-Based Vergence/Accommodative Therapy (NIBS-OBVAT) | Non-invasive Brain Stimulation Alone (NIBS) | Office-Based Vergence/Accommodative Therapy Alone (OBVAT with Sham Stimulation) |
|---|---|---|---|
| What is it? | Participants receive both non-invasive brain stimulation (anodal transcranial direct current stimulation) over the left frontal eye field and structured office-based vergence/accommodative therapy. | Participants receive only non-invasive brain stimulation (anodal transcranial direct current stimulation) without vision therapy procedures. | Participants receive standard office-based vergence/accommodative therapy with sham (inactive) brain stimulation. |
| Role in the trial | Tests the benefit of adding active brain stimulation to standard vision therapy for symptomatic convergence insufficiency. | Assesses whether brain stimulation alone provides benefit for convergence insufficiency compared to the other approaches. | Serves as the control group by delivering evidence-based vision therapy with sham brain stimulation, aligning with current standard care. |
| Primary use or aim | To determine if combining brain stimulation with vision therapy improves clinical outcomes for adults with symptomatic convergence insufficiency. | To evaluate if brain stimulation alone can address convergence insufficiency symptoms and measures. | To assess outcomes of structured vision therapy, an established treatment for convergence insufficiency, while controlling for placebo effects through sham stimulation. |
| How is it given or performed? | Participants undergo a 20-minute session of anodal-transcranial direct current stimulation over the left frontal eye field during each office-based vergence/accommodative therapy appointment, plus home reinforcement therapy 5 days per week. | Participants receive anodal-transcranial direct current stimulation over the left frontal eye field for approximately 20 minutes per session without additional vision therapy. | Participants attend weekly office therapy sessions where vision therapy procedures are performed, combined with a sham brain stimulation session that mimics the sensation of stimulation without real current, plus prescribed home exercises. |
| Evidence status | No published outcome results are available for this combined approach in adults; evidence is being generated by the current trial. | No published outcome results are available for brain stimulation alone in this population; the effectiveness of this approach is under clinical investigation. | High-quality evidence supports office-based vergence/accommodative therapy as effective for reducing symptoms and improving measures of convergence insufficiency. |
| Important limitations | Effectiveness and safety in adults with convergence insufficiency are unknown and will be determined by this ongoing trial. The additional time, complexity, and unknown long-term effects of combining treatments are not yet established. | There is no established clinical benefit for brain stimulation alone, and this approach is investigational. Long-term safety and effectiveness have not been studied for this use. | Office-based vergence/accommodative therapy requires regular in-office visits and adherence to home therapy. Some patients may not achieve full symptom resolution, and commitment is required for optimal outcomes. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 weeks
Participants receive 8 sessions of non-invasive brain stimulation, office-based vergence/accommodative therapy, or a combination of both depending on their assigned group. Office-based therapy includes weekly 60-minute in-office visits and home reinforcement exercises 5 days per week.
Weekly visits for up to 8 weeks
Duration - Up to 12 months post-treatment
Participants are monitored after treatment to assess long-term effects on convergence insufficiency symptoms and visual function.
Visits at 6 months and 12 months post-treatment
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Tara L Alvarez, Mitchell Scheiman, Elio M Santos...
https://pubmed.ncbi.nlm.nih.gov/33186192/Mitchell Scheiman, Marjean T Kulp, Susan A Cotter...
https://pubmed.ncbi.nlm.nih.gov/33263359/Convergence Insufficiency Treatment Trial Study Group
https://pubmed.ncbi.nlm.nih.gov/18852411/Midwestern University
Lead Sponsor